Radiotherapy of cutaneous B cell lymphomas: Our experience in 31 cases

Research output: Contribution to journalArticlepeer-review

Abstract

Purpose: Since cutaneous B cell lymphomas belong mostly to low or intermediate histologic grade of malignancy and have low tendency to spreading, a local treatment such as radiotherapy appears to be a suitable choice in the management of the disease. The authors have reviewed their cases to verify this statement. Methods and Materials: 31 patients affected by cutaneous B cell lymphomas classified as IE stage according to Ann Arbor received radiotherapy with orthovoltage techniques with total doses per field ranging from 10 to 40 Gy (median dose 30 Gy). All the patients had a minimum follow-up of 2 years. Results: All the target skin lesions underwent complete remission. In 10 patients (32.2%) the clinical remission is still lasting. In 21 cases (67.8%) a disease relapse was observed: only at skin in other sites than those previously treated in 17 (81%), at skin and lymph nodes in two cases (9.5%), at skin, bone, and lymph node in one case (4.7%), at skin and bowel in one case (4.7%). The extracutaneous involvement occurred in cases with lesions of intermediate grade malignancy. After a new course of radiotherapy for skin lesions only, and chemotherapy, surgery or megavoltage radiotherapy for the other involvements, on the whole 21 patients (67.8%) got a complete remission. Conclusion: On the basis of their results and of a review of the literature, the authors propose radiotherapy as the choice treatment of primary cutaneous B cell lymphomas.

Original languageEnglish
Pages (from-to)385-389
Number of pages5
JournalInternational Journal of Radiation Oncology Biology Physics
Volume27
Issue number2
DOIs
Publication statusPublished - Sep 30 1993

Keywords

  • B cell lymphoma
  • Cutaneous B cell lymphoma
  • Radiotherapy
  • Skin

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation

Fingerprint Dive into the research topics of 'Radiotherapy of cutaneous B cell lymphomas: Our experience in 31 cases'. Together they form a unique fingerprint.

Cite this